Down syndrome sits at the center of this dementia and brain health question.

A man with Down syndrome in Tucker, Georgia has recently joined a landmark clinical trial aimed at reducing Alzheimer’s disease risk, marking a significant milestone in specialized dementia research. This enrollment represents the first participant in the HERO Study, an investigational phase 1b trial led by Ionis Pharmaceuticals that focuses specifically on people with Down syndrome—a population facing extraordinarily high risk of developing Alzheimer’s as they age.

This development, reported in March 2026, signals a growing recognition among researchers and medical institutions that people with Down syndrome require dedicated, tailored approaches to understanding and potentially preventing Alzheimer’s disease, rather than relying solely on research conducted in the general population. The enrollment of this first participant is particularly meaningful because people with Down syndrome have over a 90 percent lifetime risk of developing Alzheimer’s dementia, and they develop it earlier and more universally than any other population. This article examines why people with Down syndrome face such elevated risk, what clinical trials are underway to address this challenge, and how researchers are building the infrastructure necessary to develop and test potential treatments designed specifically for this vulnerable population.

Why Do People with Down Syndrome Have Such High Alzheimer’s Risk?
The HERO Study and Current Clinical Trials Targeting Down Syndrome
The Research Infrastructure Supporting Down Syndrome Alzheimer’s Research
From Biomarkers to Treatments: What Drugs Are Being Tested?
Challenges in Conducting Alzheimer’s Research with People with Down Syndrome
The ABC-DS Cohort as a Foundation for Future Research
A New Direction for Down Syndrome and Dementia Prevention
Conclusion

Why Do People with Down Syndrome Have Such High Alzheimer’s Risk?

The elevated Alzheimer’s risk in people with Down syndrome stems from the genetic nature of the condition itself. Down syndrome results from having an extra copy of chromosome 21, which contains the gene for amyloid precursor protein (APP)—a molecule central to Alzheimer’s disease development. Because individuals with Down syndrome have three copies of this chromosome instead of two, they naturally produce higher levels of APP, which breaks down into amyloid-beta, the protein that accumulates in the brains of Alzheimer’s patients and is considered a primary driver of the disease.

By the fourth decade of life—meaning by the time people with Down syndrome reach their 40s—nearly all of them show elevated amyloid accumulation in their brains, a hallmark biomarker of Alzheimer’s disease. This biological reality means that Alzheimer’s prevention in people with Down syndrome is not a matter of risk reduction in the traditional sense; it is about intervening before the inevitable cognitive decline occurs. Without preventive interventions, the progression from amyloid accumulation to symptomatic dementia appears nearly universal in this population, making them the group with the highest biological predisposition to Alzheimer’s disease.

Why Do People with Down Syndrome Have Such High Alzheimer's Risk?

The HERO Study and Current Clinical Trials Targeting Down Syndrome

The HERO Study, led by ATRI Medical Director Michael Rafii, MD, PhD, represents the first major attempt to test a drug specifically designed to lower amyloid precursor protein levels in people with Down syndrome. The investigational medicine being tested is designed to work upstream of amyloid-beta production, potentially preventing or slowing the accumulation that typically begins in the fourth decade of life. The initial trial phase involves 30 participants across multiple sites in the United States and Europe, with an expected study duration of two years—a timeline that allows researchers to observe changes in biomarkers and safety profiles before expanding to larger trials.

Beyond the HERO Study, other clinical trials are also testing approaches in this population. The ALADDIN trial is examining donanemab, a monoclonal antibody that is already FDA-approved for Alzheimer’s treatment in the general population, but this represents the first time it is being formally tested in people with Down syndrome. Meanwhile, researchers at Vanderbilt University are conducting the ABATE study to test another potential Alzheimer’s treatment in this population. However, it is important to recognize that these trials remain relatively small and early-stage compared to the vast pharmaceutical development pipelines for conditions affecting larger populations, which means progress may be slower and fewer treatment options may ultimately reach patients.

The Research Infrastructure Supporting Down Syndrome Alzheimer’s Research

One of the most important developments enabling these clinical trials is the Alzheimer’s Biomarkers Consortium—Down Syndrome (ABC-DS), a longstanding research initiative that has fundamentally changed our understanding of how Alzheimer’s develops in this population. Launched in 2015 with support from the National Institute on aging (NIA) and the National Institute of Child Health and Human Development (NICHD), the ABC-DS was designed as a five-year longitudinal study with an initial enrollment goal of 120 participants. The consortium exceeded its targets substantially, eventually enrolling more than 350 participants with Down syndrome, ages 25 and older, along with sibling controls to help researchers understand genetic and environmental factors in disease development.

This research infrastructure has been invaluable for identifying biomarkers—measurable biological indicators—that can track Alzheimer’s disease progression in people with Down syndrome. The consortium’s findings have directly informed the design of newer trials like HERO, providing researchers with critical knowledge about which biomarkers to monitor, which age groups show the most rapid changes, and how to structure studies in ways that are feasible and ethical for this population. Without the foundational work of ABC-DS, the newer targeted trials would not have the scientific basis or participant networks to move forward.

The Research Infrastructure Supporting Down Syndrome Alzheimer's Research

From Biomarkers to Treatments: What Drugs Are Being Tested?

The investigational medicine in the HERO Study works by targeting amyloid precursor protein production itself, attempting to reduce the initial source of the problem rather than trying to clean up amyloid-beta after it has accumulated. This approach differs from some existing Alzheimer’s treatments, which work on the assumption that amyloid is already present and needs to be cleared from the brain. For people with Down syndrome, the prevention-focused approach makes biological sense because their amyloid accumulation begins decades before symptoms appear, suggesting there may be a critical window when intervention could be most effective.

The ALADDIN trial, by contrast, is testing donanemab, which targets amyloid-beta that has already accumulated in the brain—a strategy proven effective in early-stage Alzheimer’s disease patients in the general population. The advantage of testing donanemab in Down syndrome is that if it works, it already has regulatory approval and could potentially reach patients more quickly than a novel drug. However, the question remains whether existing Alzheimer’s treatments, developed and tested in older adults without Down syndrome, will work equally well in a genetically distinct population where the disease develops via a different pathway due to APP gene dosage effects.

Challenges in Conducting Alzheimer’s Research with People with Down Syndrome

Conducting clinical trials in people with Down syndrome requires thoughtful modifications to standard research protocols, partly because cognitive disability can affect informed consent, communication about side effects, and the ability to complete complex study procedures. Researchers must ensure that enrollment processes are genuinely voluntary and that participants and their families understand what participation involves—a more demanding ethical standard than in general-population trials. Additionally, the cognitive variability within the Down syndrome population means that some participants may be able to complete all study requirements while others may need accommodations, requiring trials to be more flexible than typical pharmaceutical studies.

Another significant challenge is that many existing Alzheimer’s biomarker studies and treatment trials have historically excluded people with Down syndrome, partly due to research design assumptions and partly due to logistical concerns. This historical exclusion means there is less comparative data available and fewer researchers with experience working with this population. The willingness of researchers like those at Ionis Pharmaceuticals and ATRI to specifically design trials for people with Down syndrome, rather than simply adapting existing studies, reflects a growing recognition that this population deserves treatments developed with their biology and needs in mind.

Challenges in Conducting Alzheimer's Research with People with Down Syndrome

The ABC-DS Cohort as a Foundation for Future Research

The ABC-DS consortium’s enrollment of over 350 participants has created something rare in medical research: a dedicated, well-characterized cohort of people with Down syndrome who have agreed to participate in long-term biomarker research. This cohort has allowed researchers to publish findings about amyloid accumulation patterns, cognitive decline trajectories, and other biological markers specific to this population. Importantly, the existence of this cohort provides a recruitment and monitoring infrastructure that newer clinical trials like HERO can build upon, reducing some of the logistical barriers that might otherwise make Down syndrome–specific trials prohibitively difficult to conduct.

A New Direction for Down Syndrome and Dementia Prevention

The emergence of the HERO Study and other Down syndrome–specific Alzheimer’s trials represents a significant shift in how the medical research community views this population. Rather than treating Down syndrome primarily as a condition requiring intellectual disability services, researchers are increasingly recognizing people with Down syndrome as a unique population with distinct neurobiology that merits specialized dementia prevention research. As the initial results from these trials emerge over the coming years, they may not only provide direct treatment options for people with Down syndrome but also yield insights about amyloid-beta biology and Alzheimer’s prevention mechanisms that could inform treatment development for the broader population.

Conclusion

The participation of a Tucker, Georgia man with Down syndrome in the landmark HERO Study signals an important turning point in Alzheimer’s research. For too long, people with Down syndrome—who face the highest biological risk of developing Alzheimer’s disease—have been largely absent from specialized dementia prevention research. With enrollment now underway and multiple trials testing different approaches, researchers are beginning to address this long-standing gap in medical knowledge and treatment development.

The coming years will reveal whether interventions targeting amyloid accumulation can slow or prevent Alzheimer’s disease in people with Down syndrome. Whatever the outcomes of individual trials, the commitment to studying this population with specialized research protocols represents recognition that good science requires understanding the distinct needs of all populations, not just the majority. For families of people with Down syndrome and for clinicians treating these individuals, these developments offer the possibility of preventive approaches grounded in decades of research into Down syndrome biology and the natural history of Alzheimer’s disease in this population.